US 12,245,997 B2
Endoxifen for the treatment of bipolar I disorder
Ateeq Ahmad, Wadsworth, IL (US); Imran Ahmad, Libertyville, IL (US); Moghisuddin Ahmad, Wadsworth, IL (US); Shoukath M Ali, Vernon Hills, IL (US); and Saifuddin Sheikh, Libertyville, IL (US)
Assigned to Jina Pharmaceuticals, Inc., Libertyville, IL (US)
Filed by Jina Pharmaceuticals, Inc., Libertyville, IL (US)
Filed on Apr. 9, 2021, as Appl. No. 17/226,671.
Claims priority of provisional application 63/008,162, filed on Apr. 10, 2020.
Prior Publication US 2021/0315845 A1, Oct. 14, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/28 (2006.01); A61K 9/00 (2006.01); A61K 31/138 (2006.01); A61P 25/18 (2006.01)
CPC A61K 31/138 (2013.01) [A61K 9/0053 (2013.01); A61K 9/28 (2013.01); A61P 25/18 (2018.01)] 10 Claims
 
1. A method for maintaining a therapeutically effective concentration of endoxifen for treatment of a patient with bipolar I disorder, said method comprising:
administering to the patient, a dose in a range from 2 mg to 16 mg of endoxifen citrate in an enteric coated tablet once per day for up to 21 days,
wherein the method does not include a rescue medication for the treatment of the bipolar I disorder.